Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OV PRECISION: Tumor- and Patient-specific Cancer Therapy in Ovarian Cancer
NCT06466382Recruiting
- Sponsor
- Swiss GO Trial Group
- Start
- Mar 2025
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Randomised, open-label trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Swiss GO Trial Group. Primary endpoints: Proportion of patients for whom the molecular Tumor Board (mTB) considers a different treatment option, Investigation whether the treating oncologist feels better supported by the mTB recommendation and 2 more. Started Mar 2025; status: recruiting.
02
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT06466382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06466382.